NCCIH Director Briggs Leaving: Health And Wellness Industry News
This article was originally published in The Rose Sheet
NCCIH Director Josephine Briggs will depart the center after nine years, with deputy director David Shurtleff serving as acting director; the 10th Circuit will not rehear MusclePharm's complaint against insurer; blood sugar supplement firm receives FDA warning letter; more news in brief.
You may also be interested in...
MusclePharm maintains Liberty Insurance Underwriters breached its policy and should reimburse $3m the firm spent defending SEC charges of accounting and disclosure violations. The insurer argues it was not responsible for the period during which the SEC conducted its investigation.
In an interview with “The Tan Sheet,” Briggs discusses topics including the lack of data on drug-supplement interactions and NCCIH’s interest in funding research on standards for assessing the clinical importance of those interactions.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.